People · Operator
Named in public records as an officer, director or promoter · active 2010–2020 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| ChromaDex Corp. | — | Biotechnology | Series B | $110.4M | $46.9M | 2020 |
| Vbi Vaccines Inc. | — | Biotechnology | Series B | $53.6M | $249.5M | 2014 |
| VBI Vaccines Inc/BC | — | Pharmaceuticals | Series A | $41.6M | $145.6M | 2016 |
| Variation Biotechnologies (US), Inc. | — | Biotechnology | Series A | $17.1M | $54.2M | 2010 |
Jeff Baxter at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jeff Baxter on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Egidio Nascimento | 3 | 3 |
| Steven Gillis | 2 | 23 |
| David Anderson | 2 | 21 |
| Steve Gillis | 2 | 13 |
| Steven Rubin | 2 | 7 |
| David E. Anderson | 2 | 3 |
| James Martin | 1 | 9 |
| SCOTT ROCKLAGE | 1 | 9 |
| Mark Friedman | 1 | 8 |
| MICHAEL BRAUSER | 1 | 6 |
| Barry Honig | 1 | 6 |
| Scott Requadt | 1 | 5 |
| Jeffrey Leiden | 1 | 4 |
| Michael Steinmetz | 1 | 4 |
| Stephen Block | 1 | 3 |
| Kevin Forrest | 1 | 3 |
| Thomas Varvaro | 1 | 3 |
| Glenn L. Halpryn | 1 | 3 |
| FRANCISCO DIAZ-MITOMA | 1 | 3 |
| Tomer Kariv | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.